^
4ms
New P3 trial • Combination therapy
|
dexamethasone • pomalidomide • SG301 IV
8ms
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Withdrawn --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV
over1year
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
P1, N=0, Withdrawn, Hangzhou Sumgen Biotech Co., Ltd. | N=108 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV
almost4years
Clinical • New P1 trial
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV